Amgen and AstraZeneca to collaborate on inflammation portfolio

Amgen and AstraZeneca (AZ) announced on 2 April 2012 that they will jointly develop and commercialize 5 monoclonal antibodies (mABs) from Amgen’s clinical stage inflammation portfolio.  The deal includes a relatively modest up-front payment of $50 million, and will see AZ and … Continue reading